NASDAQ:DCOY Decoy Therapeutics Q2 2026 Earnings Results & Report $1.06 -0.04 (-3.21%) Closing price 03:50 PM EasternExtended Trading$1.06 +0.01 (+0.47%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Decoy Therapeutics reported Q2 2026 earnings on August 12, 2026. The company reported EPS of -$4.46, while revenue was $227.63 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 12, 2026TimeAfter Market Closes Decoy Therapeutics EPS ResultsActual EPS-$4.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADecoy Therapeutics Revenue ResultsActual Revenue$227.63 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Decoy Therapeutics Q2 2026 Earnings FAQ Did Decoy Therapeutics beat earnings estimates for Q2 2026? Decoy Therapeutics (NASDAQ:DCOY) reported earnings of -$4.46 per share for Q2 2026. The report was announced on Wednesday, August 12, 2026. What was Decoy Therapeutics' revenue for Q2 2026? Decoy Therapeutics reported revenue of $227.63 thousand for Q2 2026. Decoy Therapeutics Earnings HeadlinesDecoy Therapeutics Named BioTech Breakthrough’s 2026 R&D Solution of the Year for IMP³ACT PlatformNovember 10 at 9:51 AM | quiverquant.comQDecoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough AwardsNovember 10 at 9:47 AM | globenewswire.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 12 at 1:00 AM | Weiss Ratings (Ad)Decoy Therapeutics Provides Third Quarter 2026 Business UpdateNovember 3, 2026 | globenewswire.comDecoy Therapeutics consensus price target cut by 90.00% to $3.06October 2, 2026 | msn.comDecoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoVSeptember 30, 2026 | rttnews.comSee More Decoy Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Decoy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Decoy Therapeutics and other key companies, straight to your email. Email Address About Decoy TherapeuticsDecoy Therapeutics (NASDAQ:DCOY) is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms. The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies. Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited. Additional details may become available as the company advances its development programs and provides further corporate disclosures.View Decoy Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
